Related Experiment Video
Updated: Jun 23, 2026
12:47
Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins
Published on: December 27, 2016
An impedimetric microelectrode-based array sensor for label-free detection of tau hyperphosphorylation in human cells
Heinz-Georg Jahnke1, Andrée Rothermel, Ina Sternberger
1Centre for Biotechnology and Biomedicine (BBZ), University of Leipzig, Division of Molecular Biological-Biochemical Processing Technology, Deutscher Platz 5, 04103, Leipzig, Germany.
Lab on a Chip
|May 7, 2009
Summary
This study introduces a new label-free method using impedance spectroscopy to detect harmful tau protein in Alzheimer's disease (AD) models. This technique helps test potential drugs targeting tau hyperphosphorylation more efficiently.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Tauopathies, including Alzheimer's disease (AD), are linked to tau protein hyperphosphorylation, causing neuronal damage and cognitive decline.
- Targeting tau hyperphosphorylation with kinase inhibitors offers a promising therapeutic strategy for neurodegenerative diseases.
Purpose of the Study:
- To develop a fast, sensitive, label-free in vitro technique for evaluating tau kinase inhibitors.
- To assess the potential of microelectrode-based impedance spectroscopy for detecting pathological tau in neuroblastoma cells.
Main Methods:
- Utilized microelectrode-based impedance spectroscopy.
- Employed the human neuroblastoma cell line SH-SY5Y.
- Tested the detection of hyperphosphorylated tau and its pathological risk potential.
Main Results:
- Demonstrated that impedance spectroscopy can detect the pathological risk of hyperphosphorylated tau in SH-SY5Y cells.
- Established a novel real-time recording technique for assessing tau kinase inhibitor efficacy.
Conclusions:
- Microelectrode-based impedance spectroscopy is a viable method for real-time assessment of tau kinase inhibitors.
- This technique can accelerate the drug discovery process for Alzheimer's disease and other tauopathies.
